Unknown

Dataset Information

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial.


ABSTRACT:

Background

Booster vaccination is an efficient way to address the waning protection of vaccines and immune escape of SARS-CoV-2 variants. We aimed to assess the safety and immunogenicity of SCTV01C, a novel bivalent protein vaccine as a booster for people who previously received two doses of mRNA vaccine.

Methods

In this randomized, phase 1/2 trial, adults fully vaccinated with mRNA vaccines 3-24 month earlier were enrolled. Participants received SCTV01C at 20 μg, 40 μg or placebo. The primary endpoints were adverse reactions within 7 days and immunogenicity on Day 28 after vaccination. This trial was registered with ClinicalTrials.gov (NCT05043311).

Findings

Between January 27 and April 28, 2022, 234 adults were randomly assigned to receive SCTV01C or placebo. The mo

SUBMITTER: Hannawi S 

PROVIDER: S-EPMC9720098 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature